Stephen Gerard Donnelly
Finanzdirektor/CFO bei KalVista Pharmaceuticals Ltd.
Aktive Positionen von Stephen Gerard Donnelly
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Unternehmenssekretär | 01.04.2008 | - |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Finanzdirektor/CFO | - | - |
Unternehmenssekretär | - | - |
Karriereverlauf von Stephen Gerard Donnelly
Ehemalige bekannte Positionen von Stephen Gerard Donnelly
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
The NASDAQ Stock Market, Inc.
The NASDAQ Stock Market, Inc. Investment Banks/BrokersFinance The NASDAQ Stock Market, Inc. is the U.S. electronic stock market. With approximately 3,300 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks | Verwaltungsdirektor | - | - |
Finanzdirektor/CFO | - | - | |
Rodaris Pharmaceuticals | Direktor/Vorstandsmitglied | - | - |
Unternehmenssekretär | - | - | |
Anagen Plc | Comptroller/Controller/Auditor | - | - |
Unternehmenssekretär | - | - |
Statistik
International
Vereinigtes Königreich | 4 |
Vereinigte Staaten | 3 |
Operativ
Corporate Secretary | 4 |
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Sektoral
Commercial Services | 2 |
Electronic Technology | 2 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
Anagen Plc | Electronic Technology |
The NASDAQ Stock Market, Inc.
The NASDAQ Stock Market, Inc. Investment Banks/BrokersFinance The NASDAQ Stock Market, Inc. is the U.S. electronic stock market. With approximately 3,300 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. It is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks | Finance |
Rodaris Pharmaceuticals | |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Stephen Gerard Donnelly
- Erfahrung